Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-227A and AD-227B Combination in Essential Hypertension
NCT06441630Phase 3Recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Jul 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AD-227B and AD-227A in essential hypertension (3 arms), sponsored by Addpharma, Inc. Primary endpoint: Change in Mean Sitting Systolic Blood Pressure at 8 weeks. Started Jul 2024; status: recruiting.
02
Drugs
AD-227BAD-227A
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06441630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441630.